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Introduction
Congenital hearing loss is one of the most common birth
defects worldwide. Estimates show that prelingual congenital
hearing loss affects approximately 1 in 1,000 children, with an
additional 1 in 1,000 people experiencing postlingual severe
hearing loss.1,2 Roughly 15% of all congenital hearing loss is
syndromic.2,3 While over 400 different syndromes involving
some degree of hearing loss have been described, it is impor-
tant to be familiar with a wide range of syndromes involving
hearing loss so an early diagnosis can be made and early
intervention can be pursued to establish, preserve, or restore
functional hearing to maximize speech-language develop-
ment in the setting of verbal communication. This review
sets out to describe the clinical presentation and most com-
mon genetics for some of the most frequently occurring
syndromes involving hearing loss.
Autosomal Dominant Syndromes
Neurofibromatosis Type 2
Neurofibromatosis type 2 (NF2, OMIM 101000), is character-
ized by the development of bilateral vestibular schwannomas
(VS) with multiple other meningiomas, optic gliomas, epen-
dymomas, and other spinal tumors.4NF2 definitive diagnostic
criteria include bilateral VS or family history of NF2 in a first-
degree relative, plus either of the following: (1) unilateral VS at
age younger than 30, or (2) any two of the following: menin-
gioma, glioma, schwannoma,or juvenileposterior subcapsular
lenticular opacities/juvenile cortical cataract.4 Hearing loss is
the most common presenting symptom in NF2 and is usually
high frequency and sensorineural.5,6 Associated findings of
facial nerve paresis or paralysis, tinnitus, vertigo, and other
balance problems can be seen as well.4
NF2 is an autosomal dominant disease, and 50% of children
of affected individuals are at risk for developing the disease. Of
patients inwhomNF2 is diagnosed, 50% present with a family
history of NF2. Half of all NF2-affected patients have no family
history of NF2 and are considered founder cases.4 The inci-
dence of NF2 is 1 per 25,000 live births.7 The NF2 gene (OMIM
607379), locatedonchromosome22q12.17, codes foraprotein
called Merlin or Schwannomin.8 This protein is a tumor sup-
pressor that helps correct F-actin cytoskeletal defects found in
schwannomas.9 Several additional genes affecting a wide
range of pathways—including angiogenesis, tumor suppres-
sion, and vascular endothelial growth factor (VEGF) inhibition,
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to name a few—appear to become deregulated in NF2, though
the specific mechanism is not fully understood at this time.10
Branchio-Oto-Renal Syndrome
As the name implies, branchio-oto-renal syndrome (BOR) can
involve anomalies of thebranchial arch system, ears, and renal
system. In terms of clinical presentation from an otologic
perspective, BOR can have outer, middle, or inner ear mani-
festations. External ear anomalies include preauricular pits or
tags (82%), malformation of the auricle (32%), microtia, and
narrowing of the external auditory canal.11–13 Middle ear
anomalies include absence of the oval window, facial nerve
dehiscence, decreased size of the middle ear cleft, and fusion,
displacement, or underdevelopment of the osicles.11 Inner ear
anomalies include cochleardysplasia andhypoplasia, enlarged
vestibular aqueduct (EVA), and lateral semicircular canal irre-
gularities.14 Some degree of hearing impairment is seen in up
to 90% of patients, most frequently a mixed loss (50%), but
sometimes exclusively conductive (30%) or sensorineural
(20%).13 Thirty-five percent of affected individuals experience
severehearing loss, and approximately25%of individuals have
a progressive loss.13Most commonly, branchial anomalies are
present in roughly half of affected individuals, and typically
manifest as lateral cervical fistulae, sinuses, and cysts. Renal
anomalies occur in approximately 65% of cases and include
agenesis (most commonly), hypoplasia, and dysplasia.13 Less
commonly, lacrimal duct aplasia, short palate, retrognathia,
and benign intracranial tumors are seen.13
BOR is transmitted in an autosomal dominant fashion with
penetrance approaching 100%. BOR is seen in approximately 1
inevery40,000births,but it isnoted inroughly1outofevery50
profoundly deaf children.13,15 The EYA1 gene (OMIM 601653),
identified at chromosome 8q13.3, has been shown to underlie
the disease, with two other genes of the same family, EYA2
(OMIM 601654) and EYA3 (OMIM 601655), as less common
causes.16,17 Relatively recently, two additional genes, SIX1
(OMIM601205)andSIX5 (OMIM600963), havebeen identified
to play a role in BOR as well.18,19 SIX proteins translocate EYA
proteins from the cytoplasm to the nucleus. EYAs work as
transcriptional coactivators upon recruitment by the SIX pro-
tein, and the SIX protein is transformed into a strong transcrip-
tion activator after interaction with EYA.20 More specifically,
EYA1 and SIX1 products work together to initiate neuronal
development of the inner ear and can also induce differentia-
tion of cochlear neurosensory stem cells to hair cells.20
Treacher Collins Syndrome
First broadly described by Edward Treacher Collins in 1900,
then more completely by Franceschetti and Klein in 1949,
Treacher Collins syndrome (TCS) or mandibulofacial dysos-
tosis is a syndrome with characteristic craniofacial abnorm-
alities and conductive hearing loss. Common presenting
features include hypoplastic facial bones, particularly the
mandible and zygomatic complex, with resulting malocclu-
sion, high-arched palate, and occasional clefting.21 Down-
ward slanting palpebral fissures, notching of lower eyelids,
and decreased eyelashes medial to lid defect are also com-
monly seen.21 From an aural and auditory standpoint, auri-
cular malformations are commonly seen, including atresia of
the external auditory canals and ossicular anomalies.21,22
Much variation has been shown in TCS patients with regard
to the ossicles and middle ear space in general, including
missing or grossly malformed ossicles, ossicular fusion,
absent or malformed oval window, and even total absence
of the middle ear and epitympanic space.21,22 These defects
predictably lead to conductive hearing impairment, but
sensorineural or mixed hearing loss is uncommon.21–23
Treacher Collins is transmitted in an autosomal dominant
fashion.24 Incidence is reported at roughly 1 in 50,000,
though approximately 50% of cases are believed to be de
novo mutations.21,24–26 Most cases of TCS can be traced to
mutations of the TCOF1 (OMIM 606847) gene on chromo-
some 5q32–33.1, which codes for a protein of uncertain
function called treacle.24 Less commonly, mutations in
POLR1D (OMIM 613715) and POLR1C (OMIM 610060) are
responsible for TCS, and these genes code for RNA polymer-
ase subunits involved in rRNA transcription.27,28
Stickler Syndrome
Stickler syndrome (SS) is an autosomal dominantly inherited
disorder of collagen connective tissue with predominantly
ophthalmic, orofacial, auditory, and articular manifesta-
tions.29,30 Diagnostic criteria include a congenital vitreous
anomaly, and any three of the following: myopia at younger
than 6 years of age, rhegmatogenous retinal detachment or
paravascular pigmented lattice degeneration, joint hypermo-
bility with abnormal Beighton score, sensorineural hearing
loss (SNHL) noted on audiometric assessment, or midline
clefting.29 Micrognathia is seen in up to two-thirds of cases,
and when severe leads to Robin sequence.29,31,32 Clefting can
manifest across abroad spectrum, fromcompletehardandsoft
palate clefting to bifid uvula or submucous clefting.30,32,33
Craniofacialanomalies suchashypertelorism, epicanthal folds,
flattenedmidface, short upturned nose, or a long philtrum can
be seen as well.34–36 Conductive, pure sensorineural, and
mixed hearing loss have all been reportedwith SS. Conductive
loss in SS typically results from Eustachian tube dysfunction
that is frequently seen with craniofacial defects.32 While
incidence of SNHL increases with age, the pathogenesis of
SNHL is incompletely understood. Possible mechanisms
include alterations in the pigmented epithelium of the inner
ear or abnormalities of inner ear collagen from autoantibo-
dies.31,37 Computed tomography has not shown evidence of
gross structural abnormalities.32 From an ocular standpoint,
most SS patients are myopic, but vitreoretinal degeneration,
retinal detachment, cataract, and blindness can also occur,
with retinal detachment leading to blindness seen in approxi-
mately half of SS patients.29,30
SS has an autosomal dominant inheritance pattern and is
caused by mutations in the COL2A1 (OMIM 120140), COL11A2
(OMIM 120290), or COL11A1 (OMIM 120280) genes that
encode for the constituent proteins of type II and type XI
collagen.38–40 Type I SS (STL1) (OMIM 108300) is caused by
mutations in COL2A1.38 This phenotype includes the classic
ocular findings with a “membranous” vitreous, and often,
palate deformities are seen. Patients with STL1 have either
Journal of Pediatric Genetics Vol. 7 No. 1/2018
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normal hearing or only a mild impairment.41 Type II SS (STL2)
(OMIM 604841) results frommissensemutations in COL11A2,
and interestingly, no ocular anomalies are seen in STL2 as the
causative gene is not expressed in the vitreous.40Hearing loss
in STL2 is moderate.41 Type III SS (STL3) (OMIM 184840) is
caused by mutations in COL11A2.40 Of note, autosomal reces-
sive forms of SS with phenotype similar to STL3 exist due to
mutations of COL9A1 (STL4) (OMIM 614134) and COL9A2
(STL5) (OMIM 614284), though palate defects are rarely
seen.42,43 Patients with STL3 tend to have moderate to severe
hearing loss in childhood, and generally do not have the
vitreous irregularities seen in STL1.41
Waardenburg Syndrome
Waardenburg syndrome (WS) refers to a condition affecting
pigmented cells in various locations of the body, including
the stria vascularis of the cochlea.44,45 WS is subdivided into
four distinct types. Type I WS (WS1) (OMIM 193500) is
characterized by dystopia canthorum, an involuntary dis-
placement of the inner canthi and lacrimal puncti giving the
impression of a widened nasal bridge.44,45 Additional fea-
tures often include heterochromia iridium (pale blue eye),
white forelock, synophrys, broad nasal root, hypoplasia of
the alae nasi, patent metopic suture line, and a square
jaw.44–46 Hearing impairment is seen in between one-third
and two-thirds of WS1 patients.47,48 In type II WS (WS2,
OMIM 193510), presentation is largely the same as WS1
without dystopia canthorum.48 Congenital deafness is seen
in just over half up to as many as 85% of WS2 patients.47,48
Type III WS (WS3) (OMIM 148820), also known as Klein–
Waardenburg Syndrome, has similar presentation as WS1,
with the addition of musculoskeletal abnormalities such as
limb and digit defects.49 Type IV WS (WS4) (OMIM 277580),
also known as Shah–Waardenburg Syndrome or Waarden-
burg–Hirschsprung disease has similar presentation to WS1
with the addition of Hisrchsprung’s disease features (agan-
glionic megacolon).50
Initially, WS (all variants taken together) had an esti-
mated prevalence of 1 in 42,000, but more recent studies
estimate the prevalence is closer to 1 to 2 per 20,000 with
an incidence of 1 to 2 per 8,400.45,51 WS1 is caused by
mutations in PAX3 (OMIM 606597), which is expressed in
neural crest cells in early development, and melanocytes,
including those in the stria vascularis, can thus be absent in
WS1 patients.45 PAX3 also plays a role in limb bud devel-
opment, so it is believed to be responsible for WS3 pheno-
typic findings.45 While there is a greater degree of
heterogeneity in the underlying genetics of WS2 phenoty-
pic individuals, mutations in the microphthalmia (MITF)
(OMIM 156845) gene, a transcription factor that, like
PAX3, plays a role in melanocyte development have been
found in roughly 15% of affected individulas.45,52 Mutations
in SNAI2 (OMIM 602150) transcription factor involved in
neural crest cell migration, have also been shown to cause
WS2.53 Endothelin 3 (EDN3) (OMIM 131242), endothelin
receptor B (EDNRB) (OMIM 131244), and SOX10 (OMIM
602229) genes have been rarely associated with WS2, but
mutations of each of the three genes is more commonly
seen in WS4.52–55 WS1 and WS3 are always thought to be
autosomal dominant, while WS2 is mostly dominant with
rare cases of autosomal recessive inheritance being seen,
and WS4 is thought to always be recessive.49,52,53,55–57
Autosomal Recessive Syndromes
Pendred Syndrome
Pendred syndrome (OMIM 274600) is an autosomal reces-
sive disorder characterized by sensorineural deafness, goiter,
and a partial defect in iodide organification.58 First described
in the literature by Pendred in 1896, deafness is often the
presenting symptom, and in the majority of cases the deaf-
ness is prelingual.47,59,60 Accompanying the sensorineural
deafness are inner ear malformations including enlargement
of the endolymphatic system, often seen on imaging as an
EVA.61 Some patients also have been shown to have a
Mondini malformation, where only the basal one and a
half turns are present instead of the typical coiled scala.62
Thyroid enlargement can varywidely fromnormal thyroid to
significant goiter that can impinge upon the airway.63 Nor-
mally, less than 10% of radioiodide accumulated in thyro-
cytes are not rapidly organified into thyroglobulin for the
purpose of thyroid hormone synthesis. In contrast, patients
with Pendred syndrome lose more than 15% thus indicating
an impaired iodide organification.59,62 Despite the variation
in iodide organification, most patients with Pendred are
euthyroid unless they have deficient dietary iodine.64
Pendred syndrome is inherited in an autosomal recessive
fashion and results from amutation of the PDS/SLC26A4 gene
(OMIM 605646) on chromosome 7.65 The affected gene codes
for an ion transporter protein named pendrin, most abun-
dantly expressed in the thyroid, inner ear, and kidney.64,65 In
Pendred syndrome, the SLC26A4mutation is biallelic, but EVA
can be observed in nonsyndromic hearing loss if there is
homozygosity for the SLC26A4wild-type or only one mutated
allele.64,66 Overall, it is estimated that Pendred syndrome
accounts for up to 10% of hereditary hearing loss with and
incidence of 7.5 to 10 in 100,000.62,63
Jervell and Lange-Nielsen Syndrome
Jervell and Lange-Nielsen syndrome (JLNS) was first described
in 1957 by Jervell and Lange-Nielsen in a Norwegian family in
which four of six siblings had congenital deafness, marked
prolongation of the QT interval, and multiple syncopal attacks
induced by exercise or emotion.67,68 JLNS is inherited in auto-
somal dominant fashion. QT prolongation without congenital
deafnessmaybe inherited indominantor recessive fashion, and
the more common dominant disease is known as Romano–
Ward syndrome.69 Mutations of the KCNQ1 gene (JLNS1)
(OMIM 607542) on chromosome 11 and mutations of the
KCNE1 gene (JLNS2) (OMIM 176261) on chromosome 21
havebeen shown to result in the JLNSphenotype, each affecting
ion transport channels in the heart and the inner ear.69–71
Though prevalence of JLNS is low at 0.21%, malignant courses
areknowntoresult insuddendeathatayoungage.Additionally,
as treatment of the disease with β-blockers can reduce rates of
sudden death from 71 to 6%, early identification is critical.68,72
Journal of Pediatric Genetics Vol. 7 No. 1/2018
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Usher Syndromes
Though clinical presentation can vary widely, Usher syn-
dromes are classically characterized by SNHL and retinitis
pigmentosa.73 While the genetics of the Usher syndromes
have much heterogeneity, there are three known clinical
subtypes.74 Type 1 Usher syndrome (USH1) is the most
severe, with congenital bilateral SNHL, constant vestibular
dysfunction, and prepubertal retinitis pigmentosa.74 Vestib-
ular dysfunction in USH1 patients usually presents clinically
as delays in motor development, with delay in sitting up
unsupported and inability to walk younger than age
18 months.75 As vision worsens over time, USH1 patients
also develop more severe gait disturbances.75 The retino-
pathy appears as a loss of night vision and a restriction of the
visual field during childhood, and eventually, as a visual
acuity loss that rapidly progresses to blindness.74 Type 2
Usher syndrome (USH2) is notable for less severe deafness,
absence of vestibular symptoms, and generally later onset of
vision loss, typically around the age of puberty.74 Type 3
Usher syndrome (USH3) much less common, but it is char-
acterized by progressive hearing loss and occasional vestib-
ular dysfunction in addition to retinitis pigmentosa around
puberty.74,76 In all three subtypes, cataracts may develop in
addition to retinitis pigmentosa.77
Asmentioned above,much genetic heterogeneity exists in
the Usher syndromes. USH2 is generally accepted as being
themost commonphenotype, but exact estimates of ratios of
USH1:USH2 vary.73,78 Though there are at least 13 different
genes accounting for the three different clinical subtypes of
Usher syndrome, 2 of these, USH1B (OMIM 276900) and
USH2A (608400), account for up to 80% of all Usher syndrome
cases (see ►Table 1 for a more detailed list of Usher syn-
drome genes).78 USH1B is caused by a mutation in the
MYO7A gene (OMIM 276903) on chromosome 11, and this
subtype is believed to account for three quarters of all
USH1.79 MYO7A codes for myosin-VIIa, an unconventional
member of the large superfamily of myosin motor proteins
that move on cytoplasmic actin filaments present, among
other places, on the inner and outer hair cells in the organ of
Corti.73,79,80 USH2A is the most common form of USH2 and
has been shown to result from amutation in the USH2A gene
on chromosome 1.81,82USH2A codes for “Usherin,” a putative
extracellular matrix protein.82 Incidence was historically
believed to be approximately 4.4 in 100,000, which repre-
sents 3 to 6% of congenitally deaf persons in theUnited States,
but more recent evidence suggests that number may be far
too small, with actual incidence closer to 1 in 6,000.83,84
Table 1 Summary of covered syndromes
Mode of
inheritance
Syndrome Locus/Gene OMIM
number
Autosomal
dominant
Neurofibromatosis 2 NF2 607379
Branchio-oto-renal
syndrome
EYA1 601653
EYA2 601654
EYA3 601655
SIX1 601205
SIX5 600963
Treacher Collins TCOF1 606847
POLR1D 613715
POLR1C 610060
Stickler syndrome STL1/COL2A1 120140
STL2/COL11A2 120290
STL3/COL11A1 120280
STL4/COL9A1 614134
STL5/COL9A2 614284
Waardenburg
syndrome
PAX3 606597
Table 1 (Continued)
Mode of
inheritance
Syndrome Locus/Gene OMIM
number
MITF 156845
SNAI2 602150
EDN3 131242
EDNRB 131244
SOX10 602229
Autosomal
recessive
Pendred syndrome PDS/SLC26A4 605646
Jervell and Lange–
Nielsen syndrome
JLNS1/KCNQ1 607542
JLNS2/KCNE1 176261
Usher syndrome USH1B/MYO7A 276903
USH1C 605242
USH1D/CDH23 605516
USH1E 602097
USH1F/PCDH15 605514
USH1G/SANS 607696
USH1H 612632
USH1J/CIB2 605564
USH1K 614990
USH2A 608400
USH2C/ADGRV1 602851
USH2D/WHRN 607928
USH3A/CLRN1 606397
USH3B/HARS 142810
Refsum disease PHYH/PAHX 602026
PEX7 601757
X-linked
dominant
Alport syndrome COL4A5 303630
COL4A3 120070
COL4A4 120131
Mitochondrial MELAS MTTL1 590050
MERRF MTTK 590060
Abbreviations: MELAS, mitochondrial encephalomyopathy, lactic
acidosis, and stroke-like episodes; MERRF, myoclonic epilepsy with
ragged red fibers; OMIM, Online Mendelian Inheritance in Man.
Journal of Pediatric Genetics Vol. 7 No. 1/2018
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Refsum Disease
Refsum disease (OMIM 266500) is characterized by periph-
eral polyneuropathy, cerebellar ataxia, retinitis pigmentosa,
and ichthyosis.85 There are also commonly elevated protein
levels in the cerebrospinal fluid without an increase in the
number of cells in the cerebrospinal fluid.86 Late sequelae of
the disease can include cardiac arrhythmias and progressive
postlingual SNHL than can become severe.87 Patients with
Refsum disease have elevated levels of phytanic acid due to a
deficiency of the peroxisomal enzyme phytanoyl-CoA hydro-
xylase, which converts phytanic acid to α-hydroxyphytanic
acid.87,88 Originally, it was thought that all forms of Refsum’s
disease resulted from mutations to the PHYH/PAHX gene
(OMIM 602026) on chromosome 10, which code for this α
hydroxylase.86,89 More recently, however, mutations to the
PEX7 gene (OMIM 601757) on chromosome 6were shown to
play a role in approximately 1 in 10 cases of Refsum
disease secondary to defects in plasmalogen synthesis and
peroxisomal thiolase.87,90 Though a rare disease with inci-
dence estimated at 1 per 1 million, it is important to
recognize this syndrome as dietary modification can slow
or prevent hearing loss aswell as palliating or reversing some
of the other clinical symptoms, such as ichthyosis.90
Other Disorders
Alport Syndrome
Alport syndrome (AS, OMIM 301050) was first described in
1927 by A. Cecil Alport with the hallmark findings of
hemorrhagic nephritis, hearing loss, and vision changes.91
Most cases of AS are transmitted in X-linked dominant
fashion, though some autosomal recessive and dominant
forms also exist.92 Clinical diagnosis can be made if four of
the following diagnostic criteria are met: family history of
hematuria, high-frequency progressive SNHL, ocular changes
including anterior lenticonus and/or macular flecks, and
glomerular basement membrane changes.93 As would be
expected in a largely X-linked syndrome, males are typically
affected more significantly than females, with most males
progressing to end-stage renal disease by their early 20s.94
Anterior lenticonus that results from inability of the lens to
hold its shape can result in myopia.95,96 Though the exact
mechanism of SNHL in AS is yet undetermined, bilateral
progressive high-frequency loss is seen inmost cases.95–97 In
X-linkedmales, 50% have somehearing loss at age 15 and 90%
have hearing loss by age 40.98 Early hearing loss often
portends worse renal damage. Nearly all patients with the
recessive form of the disease develop early hearing loss,
regardless of gender, and it is usually progressive.99
Incidence of AS is approximately 1 in 53,000.100Mutations
to the α subunits of Type IV collagen cause AS, typically
interrupting the 3 to 4-5 complex in cellular basement mem-
branes.101 In X-linked AS, comprising roughly 65 to 80% of
cases, this is due to themutation of the COL4A5 gene (303630)
which codes for the α5 subunit of type IV collagen.92,101,102
Some controversy exists as to the proportion of AS that is
autosomal recessive versus dominant, but each is caused by
varying proportions of defects in the COL4A3 (OMIM 120070)
and COL4A4 (OMIM 120131) genes, affecting the α3 and α4
subunits of type IV collagen, respectively.92,102
Mitochondrial Encephalopathy, Lactic Acidosis, and
Stroke-Like Episodes
This mitochondrial syndrome typically presents with normal
early development, short stature, nausea, migraines, seizures,
and alternating hemiparesis, hemianopia, or cortical blind-
ness.103 Hearing loss can present in approximately 30% of
patients, may occasionally be the only presenting symptom,
and it is typically a bilateral, progressive sensorineural
loss.103–105 Histopathologic analysis shows severe atrophy of
the stria vascularis in mitochondrial encephalopathy, lactic
acidosis, and stroke-like episodes (MELAS) patients.105 MELAS
(OMIM540000) is causedbypointmutations in the tRNALeu(UUR)
(MTTL1) gene (OMIM 590050), with the A3243G transition as
the most common mutation.106,107 This mutation encodes a
defective transfer RNA.107
Myoclonic Epilepsy with Ragged-Red Fibers
Another mitochondrial syndrome, MERRF (OMIM 545000)
presents with myoclonic epilepsy, ataxia, dementia, optic
atrophy, hearing loss, short stature, and neuropathy.104,106
Hearing loss is present in roughly half of patients.104,108
MERRF is caused by point mutations in the tRNA(lys)
(MTTK) gene (OMIM 590060) most often with an A8344G
translocation, again leading to defective transfer RNA.108,109
Syndromic hearing loss affects roughly 3 out of every
10,000 live births.2,3 With this prevalence, it is imperative
that one remain vigilant for early signs or symptoms thatmay
be serve as clues of multisystem problems to come. While
this review does not aim to be comprehensive, it is our hope
that it may be utilized both to guide early intervention to
establish, preserve, or restore hearing for patients as well as
to spur early engagement with an interdisciplinary team to
minimize or delay syndrome-associated morbidity.
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